...
search icon
dnth-img

Dianthus Therapeutics Inc. Share Price

DNTH
NAQ
$50.75
+$4.17
(8.95%)
1D
Industry: Biotechnology Sector: Health Care

Dianthus Therapeutics Inc. Analyst Forecast

Dianthus Therapeutics Inc. Share Price Chart

Dianthus Therapeutics Inc. Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.01B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
733.26K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$13.37 L
$57.5 H
$50.75

About Dianthus Therapeutics Inc., Common Stock

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Dianthus Therapeutics Inc. Stock Returns

Time FrameDNTHSectorS&P500
1-Week Return-4.94%0.06%-2.06%
1-Month Return40.19%-2.06%-2.06%
3-Month Return39.31%6.1%1.11%
6-Month Return148.9%18.64%7.13%
1-Year Return121.04%5.25%11.74%
3-Year Return289.52%17.35%65.43%
5-Year Return-68.96%33.7%73.53%
10-Year Return-78.16%143.77%266.66%

Dianthus Therapeutics Inc. Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-1.48M6.42M2.83M6.24M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":44.04,"profit":true},{"date":"2024-12-31","value":97.16,"profit":true}]
Cost of Revenue1.98M2.02M147.00K355.00K412.00K[{"date":"2020-12-31","value":97.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":7.28,"profit":true},{"date":"2023-12-31","value":17.57,"profit":true},{"date":"2024-12-31","value":20.4,"profit":true}]
Gross Profit(1.98M)1.48M6.42M2.83M6.24M[{"date":"2020-12-31","value":-30.82,"profit":false},{"date":"2021-12-31","value":23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":44.04,"profit":true},{"date":"2024-12-31","value":97.16,"profit":true}]
Gross Margin-100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses76.72M14.56M36.12M51.00M108.10M[{"date":"2020-12-31","value":70.98,"profit":true},{"date":"2021-12-31","value":13.47,"profit":true},{"date":"2022-12-31","value":33.42,"profit":true},{"date":"2023-12-31","value":47.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(78.70M)(13.09M)(29.70M)(48.17M)(101.86M)[{"date":"2020-12-31","value":-7870200000,"profit":false},{"date":"2021-12-31","value":-1308600000,"profit":false},{"date":"2022-12-31","value":-2970500000,"profit":false},{"date":"2023-12-31","value":-4817400000,"profit":false},{"date":"2024-12-31","value":-10186400000,"profit":false}]
Total Non-Operating Income/Expense-(20.00K)2.37M7.58M34.26M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.06,"profit":false},{"date":"2022-12-31","value":6.93,"profit":true},{"date":"2023-12-31","value":22.12,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(74.94M)(13.11M)(28.48M)(43.55M)(84.97M)[{"date":"2020-12-31","value":-7493600000,"profit":false},{"date":"2021-12-31","value":-1310900000,"profit":false},{"date":"2022-12-31","value":-2847600000,"profit":false},{"date":"2023-12-31","value":-4355500000,"profit":false},{"date":"2024-12-31","value":-8496900000,"profit":false}]
Income Taxes7.53M(2.00M)(1.28M)187.10K-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-26.51,"profit":false},{"date":"2022-12-31","value":-17.01,"profit":false},{"date":"2023-12-31","value":2.48,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-(11.11M)(27.20M)(43.74M)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1111200000,"profit":false},{"date":"2022-12-31","value":-2719500000,"profit":false},{"date":"2023-12-31","value":-4374210500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations-(13.11M)(28.48M)(43.11M)(84.97M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1310900000,"profit":false},{"date":"2022-12-31","value":-2847600000,"profit":false},{"date":"2023-12-31","value":-4310800000,"profit":false},{"date":"2024-12-31","value":-8496900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(74.94M)(13.11M)(28.48M)(43.55M)(84.97M)[{"date":"2020-12-31","value":-7493600000,"profit":false},{"date":"2021-12-31","value":-1310900000,"profit":false},{"date":"2022-12-31","value":-2847600000,"profit":false},{"date":"2023-12-31","value":-4355500000,"profit":false},{"date":"2024-12-31","value":-8496900000,"profit":false}]
EPS (Diluted)(1.74)(1.31)(1.25)(5.83)(2.58)[{"date":"2020-12-31","value":-174,"profit":false},{"date":"2021-12-31","value":-131,"profit":false},{"date":"2022-12-31","value":-125,"profit":false},{"date":"2023-12-31","value":-582.63,"profit":false},{"date":"2024-12-31","value":-258,"profit":false}]

Dianthus Therapeutics Inc. Ratios

Dianthus Therapeutics Inc. Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

DNTH
Cash Ratio 16.88
Current Ratio 17.35

Dianthus Therapeutics Inc. Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

DNTH
ROA (LTM) -18.82%
ROE (LTM) -28.57%

Dianthus Therapeutics Inc. Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

DNTH
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Dianthus Therapeutics Inc. Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

DNTH
Trailing PE NM
Forward PE NM
P/S (TTM) 654.10
P/B 3.81
Price/FCF NM
EV/R 545.48
EV/Ebitda NM

FAQs

What is Dianthus Therapeutics Inc. share price today?

Dianthus Therapeutics Inc. (DNTH) share price today is $50.75

Can Indians buy Dianthus Therapeutics Inc. shares?

Yes, Indians can buy shares of Dianthus Therapeutics Inc. (DNTH) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNTH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Dianthus Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Dianthus Therapeutics Inc. (DNTH) via the Vested app. You can start investing in Dianthus Therapeutics Inc. (DNTH) with a minimum investment of $1.

How to invest in Dianthus Therapeutics Inc. shares from India?

You can invest in shares of Dianthus Therapeutics Inc. (DNTH) via Vested in three simple steps:

  • Click on Sign Up or Invest in DNTH stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Dianthus Therapeutics Inc. shares
What is Dianthus Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Dianthus Therapeutics Inc. (DNTH) is $57.5. The 52-week low price of Dianthus Therapeutics Inc. (DNTH) is $13.37.

What is Dianthus Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Dianthus Therapeutics Inc. (DNTH) is

What is Dianthus Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Dianthus Therapeutics Inc. (DNTH) is 3.81

What is Dianthus Therapeutics Inc. dividend yield?

The dividend yield of Dianthus Therapeutics Inc. (DNTH) is 0.00%

What is the Market Cap of Dianthus Therapeutics Inc.?

The market capitalization of Dianthus Therapeutics Inc. (DNTH) is $2.01B

What is Dianthus Therapeutics Inc.'s stock symbol?

The stock symbol (or ticker) of Dianthus Therapeutics Inc. is DNTH

How Can Investors Use Dianthus Therapeutics Inc. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Dianthus Therapeutics Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Dianthus Therapeutics Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Dianthus Therapeutics Inc. shares for Indian investors?

When investing in Dianthus Therapeutics Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Dianthus Therapeutics Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Dianthus Therapeutics Inc. share price with other stocks in the same sector?

Rather than merely checking the share price of Dianthus Therapeutics Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Dianthus Therapeutics Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top